An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 120
- Registration Number
- NCT00131612
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
Phase 1
Terminated
- Conditions
- Esophageal CancerGastric CancerTumors
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 50
- Registration Number
- NCT00130936
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Tomotherapy in Patients With Benign Brain Tumour
Phase 1
Completed
- Conditions
- Brain Neoplasms
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 49
- Registration Number
- NCT00128986
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Self-Gated Breath-Hold Technique for Helical Tomotherapy in Patients With Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 30
- Registration Number
- NCT00129012
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Improving Assessment (and Ultimately Outcomes) of Permanent Prostate Implant Therapy
Not Applicable
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT00127816
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 1000
- Registration Number
- NCT00126815
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to Capecitabine Chemotherapy in Colon Cancer Treatment
Terminated
- Conditions
- Colon Cancer
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 29
- Registration Number
- NCT00126867
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer
Phase 1
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 60
- Registration Number
- NCT00126802
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation
Not Applicable
Completed
- Conditions
- Prostatic Neoplasm
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 10
- Registration Number
- NCT00126854
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Small Cell
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 18
- Registration Number
- NCT00126828
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath